Novo Nordisk A/SNOV
▼ NegativeTechnologyrelevance
ZEUS phase 3 trial for ziltivekimab failed to reduce major adverse cardiovascular events versus placebo.
Impact on stocks 1
Biotech & Genomic Medicine
Novo Nordisk A/SNovo Nordisk shares fell 8.78% in a single day after the ZEUS phase 3 trial for heart drug candidate ziltivekimab failed to reduce major adverse cardiovascular events versus placebo. The stock is down 10.14% year to date, though the 90-day return is up 7.29% and the one-year total shareholder return is slightly positive at 0.92%. Novo Nordisk now trades at a small 3% discount to average analyst targets, while internal estimates suggest a much steeper 52% gap to intrinsic value. The most followed narrative on the stock pitches a fair value of $102.97 against the last close of $47.08, implying a 54% undervaluation, driven by catalysts such as a successful phase IIIa trial of oral semaglutide in adolescents with Type II diabetes.
Novo Nordisk A/SZEUS phase 3 trial for ziltivekimab failed to reduce major adverse cardiovascular events versus placebo.